Glycosylated specificity exchangers

Details Glycosylated specificity exchangers Glycosylated specificity exchangers

2008-01-15

2008-01-15

Parkin, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S193100, C424S196110, C514S001000, C514S008100

Reexamination Certificate

active

10773628

ABSTRACT:
The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.

REFERENCES:
patent: 4169138 (1979-09-01), Jonsson
patent: 4376110 (1983-03-01), David et al.
patent: 4471058 (1984-09-01), Smith et al.
patent: 4486530 (1984-12-01), David et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5260189 (1993-11-01), Formoso et al.
patent: 5320951 (1994-06-01), Hook et al.
patent: 5416021 (1995-05-01), Hook et al.
patent: 5440014 (1995-08-01), Hook et al.
patent: 5561049 (1996-10-01), Vold et al.
patent: 5571511 (1996-11-01), Fischer
patent: 5571514 (1996-11-01), Hook et al.
patent: 5582975 (1996-12-01), Milliman
patent: 5583042 (1996-12-01), Roth
patent: 5601830 (1997-02-01), Su et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5652217 (1997-07-01), Hook et al.
patent: 5700928 (1997-12-01), Hodgson et al.
patent: 5714332 (1998-02-01), Lussow et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5766857 (1998-06-01), Ruoslahti et al.
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5770702 (1998-06-01), Hook et al.
patent: 5776712 (1998-07-01), Kuusela et al.
patent: 5789549 (1998-08-01), Hook et al.
patent: 5840846 (1998-11-01), Hook et al.
patent: 5843774 (1998-12-01), Ginsberg
patent: 5846536 (1998-12-01), Bissell et al.
patent: 5866541 (1999-02-01), Hook et al.
patent: 5869232 (1999-02-01), Sällberg
patent: 5888738 (1999-03-01), Hendry
patent: 5922548 (1999-07-01), Lussow et al.
patent: 5929220 (1999-07-01), Tong et al.
patent: 5939273 (1999-08-01), Lussow et al.
patent: 5942606 (1999-08-01), Lal et al.
patent: 5955078 (1999-09-01), Burnham et al.
patent: 5980908 (1999-11-01), Hook et al.
patent: 5981274 (1999-11-01), Tyrrell et al.
patent: 6008341 (1999-12-01), Foster et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6040137 (2000-03-01), Sällberg
patent: 6046040 (2000-04-01), Nishiguchi et al.
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6077677 (2000-06-01), Hodgson et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6086895 (2000-07-01), Hook et al.
patent: 6087330 (2000-07-01), Kogan et al.
patent: 6090388 (2000-07-01), Wang
patent: 6090944 (2000-07-01), Hutchinson
patent: 6093539 (2000-07-01), Maddon et al.
patent: 6245895 (2001-06-01), Sällberg
patent: 6303120 (2001-10-01), Danishefsky et al.
patent: 6417324 (2002-07-01), Sällberg
patent: 6458937 (2002-10-01), Bertozzi et al.
patent: 6469143 (2002-10-01), Sällberg
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6660842 (2003-12-01), Sällberg
patent: 2002/0025513 (2002-02-01), Sällberg
patent: 2002/0058247 (2002-05-01), Sällberg
patent: 2003/0021789 (2003-01-01), Xu et al.
patent: 2003/0044418 (2003-03-01), Davis et al.
patent: 2004/0001853 (2004-01-01), George et al.
patent: 0 182 546 (1986-05-01), None
patent: 0 508 427 (1992-10-01), None
patent: 04347162 (2002-12-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 95/08577 (1995-03-01), None
patent: WO 95/22249 (1995-08-01), None
patent: WO 95/29938 (1995-11-01), None
patent: WO 98/03543 (1998-01-01), None
patent: WO 98/31389 (1998-07-01), None
patent: WO 98/43677 (1998-10-01), None
patent: WO 99/27109 (1999-06-01), None
patent: WO 99/61041 (1999-12-01), None
patent: WO 9966957 (1999-12-01), None
patent: WO 00/26385 (2000-05-01), None
patent: WO 00/66621 (2000-11-01), None
patent: WO 01/81421 (2001-11-01), None
patent: WO0182546 (2001-11-01), None
patent: WO 02/24887 (2002-03-01), None
Galili et al. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody, Vaccine 1996, vol. 14, No. 4. pp. 321-328.
Wong et al. Synthetic glycosylation of proteins using N-(B-saccharide) iodoacetamides: applications in site-specific glycosylation and solid-phase enzymic oligosaccharide synthesis. Biochemistry Journal 1994, vol. 300, p. 843-850.
Ashford et al. Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in Chinese Hamster Ovary cells. The Journal of Biological Chemistry Feb. 15, 1993, vol. 268, No. 5, p. 3260-3267.
Ennas et al., “Human ALL-1/MII/HRX Antigen is Predominantly Localized in the Nucleus of Resting and Proliferating Peripheral Blood Mononuclear Cells” Cancer Research 57, 2035-2041, May 15, 1997.
Galili et al., “Evolutionary relationship between the natural anti-Gal antibody and the Galα1→3Gal epitope in primates” Proc Natl. Acad. Sci. vol. 84, pp. 1369-1373, Mar. 1987 Immunology.
Galili et al., Human natural anti-α-galactosyl IgG: the specfic recognition of α(1→3)-linked galactose residues, J. Exp. Med., vol. 162, Aug. 1985, pp. 573-582.
Galili et al., “One percent of human ciculating B Lymphocytes are capable of producing the natural anti-gal antibody” Blood, vol. 82, No. 8, Oct. 15, 1993 pp. 2485-2493.
Leibiger H. et al.; “Structural characterization of the oligosaccharides of a human monoclonal anti-lipopolysaccharide immunoglobulin M.”; GLYCOBIOLOBY, May 1998, vol. 8, No. 5, May 1998, pp. 497-507, XP008033789; ISSN: 0959-6658; abstract; tables 2,3; p. 502, right-hand column, paragraph 3—p. 503, left-hand column, paragraph 1.
Lin S. S. et al.; “Differential recognition by proteins of alpha-galactosyl residues on endothelial cell surfaces.”; CLYCOBIOLOGY, May 1998, vol. 8, No. 5, May 1998, pp. 433-443, XP008033788; ISSN: 0959-6658; abstract; table1.
Mizukami T. et al.; “Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.” Proceedings of the National Academy of Sciences of the United States of America, Dec. 1988, vol. 85, No. 23, Dec. 1988, pp. 9273-9277, XP001194700; ISSN: 0027-8424; cited in the application; abstract; figure 1.
Barbas et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,”Proc. Natl. Acad. Sci. USA,88:7978-7982, (1991).
Bianchi, et al., “Affinity Purification of a Difficult-Sequence Protein: Implications for the Inclusion of Capping in Synthetic-Protocols.”Int. J. Pept. Protein Res.,42(1):93-96, Jul. 1993.
Bianchi, et al., “Chemical Synthesis of a Designed Beta-Protein Through the Flow-Polyamide Method”Int. J. Pept. Protein Res.,41(4):385-393, Apr. 1993.
Bichko et al., “Epitopes recognized by antibodies to denatured core protein of hepatitis B virus,”Mol. Immunol.,30(3):221-231, (1993).
Brett et al., “The invasin protein of Yersinia spp. provides co-stimulatory activity to human T cells through interaction with beta 1 integrins,”Eur. J. Immunol.,23(7):1608-1614 (1993).
Cello J, et al., “Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides,”J. Clin. Microbiol.,31(4):911-916 (1993).
Chien et al., “Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides,”Proc. Natl. Acad. Sci. USA,88:9578-9582 (1991).
Chui et al., “Genetic remodeling of protein glycosylation in vivo induces autoimmune disease,” PNAS, 98(3):1142-1147 (2001).
Cohen, J, et al., “Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes,”Proc Natl Acad Sci USA,87(13):4922-4926 (1990).
Colberre-Garapin et al., “A new dominant hybrid selective marker for hig

Affiliated with

Also associated with

Rating

Glycosylated specificity exchangers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycosylated specificity exchangers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosylated specificity exchangers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3932027